DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175083

A study on ulinastatin in preventing post ERCP pancreatitis

R. Vedamanickam, Vinoth Kumar, Hariprasad .

Abstract


Background: Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis. The aim of this study was to assess the efficacy of ulinastatin, compare to placebo study to assess the incidence of complication due to ERCPP procedure.

Methods: In this study a randomized placebo controlled trial, patients undergoing the first ERCP was randomizing to receive ulinastatin one lakh units (or) placebo by intravenous infusion one hour before ERCP for ten minutes duration. Clinical evaluation, serum amylase, ware analysed before the procedure 4 hours and 24 hours after the procedure.

Results: Total of 46 patients were enrolled (23 in ulinastatin and 23 in placebo group). The incidence of Hyper enzymemia is lower in ulinastatin group (13 %) than in placebo group (30.4%).

Conclusions: Prophylactic short-term administration of ulinastatin one lakh units intravenously, one hour before ERCP procedure is effective when compared to placebo infusion.


Keywords


Enzymemia, ERCP, Pancreatitis, Ulinastatin

Full Text:

PDF

References


Loperfido S, Angelini G, Benedetti G. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1-10.

Masci E, Toti G, Mariani A. Complications of diagnostic and therapeutic ERCP: a prospective, multicenter study. Am J Gast. 2001;96:417-23.

Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gast Endos. 2001;54(4):425-34.

Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gast. 2006;101:139-47.

Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gast Endos. 1998;48(1):1-0.

Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endos. 2007;39(09):793-801.

Wang P, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Ame J Gastroenterol. 2009;104(1):31-40.

Testoni PA, Bagnolo F, Natale C, Primignani M. Incidence of post-endoscopic retrograde-cholangiopancreatography/sphincterotomy pancreatitis depends upon definition criteria. Digestive and Liver Dis. 2000;32(5):412-8.

Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatetography. Gabexate in digestive endoscopy. N Engl J Med. 1996;335:919-23.

Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized controlled trial. Clin Gastroenterol Hepatol. 2005;3:376-83.

Ohara H, Goto K, Noguchi Y, Shiraki S, Kamiya Y, Nakayama Y, et al. The usefulness of Ulinastatin for post-ERCP pancreatitis and hyperpancreto-enzymemia-comparative examination between one-shot injection and drip infusion of ulinastatin. Gastroenterol. 1990;12:361-8.

Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, et al. Ulinastatin shows preventive effect on post endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006;21:1065-9.

Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy. Italian Group. N Engl J Med. 1996;335:919-23.

Ohara H, Goto K, Noguchi Y, Shiraki S, Kamiya Y, Nakayama Y. The usefulness of ulinastatin for post-ERCP pancreatitis and hyperpancreatoenzymemia-comparative examination between one-shot injection and drip infusion of ulinastatin. Gastroenterol. 1990;12:361-8.

Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicentre prospective randomized study. J Gastroenterol Hepatol. 2006;21:1065-9.